In a paper published today in Science Advances, University of Alabama at Birmingham researchers identify for the first time a new mechanism for this increased permeability, and they also show the ability to block it in cell culture, animal disease models, and in human specimens from patients with ARDS.
In the future, this discovery could lead to therapy to target ARDS, and also other human diseases that have extracellular matrix turnover and blood vessel leakage, including reperfusion of organs after they have been cut off from oxygen, lung vascular disease, kidney injury and heart attacks. In all of these, the critical biological function of the endothelium is altered by inflammation or disease.
Key to this new mechanism of blood vessel permeability is a small peptide called “acetylated proline-glycine-proline” (N-α-PGP). The UAB researchers have discovered that N-α-PGP is a critical regulator of endothelial permeability, and its signal couples extracellular matrix fragmentation to that leakage.
When tissue is damaged or infected, part of the inflammatory response is the release and activation of proteases that degrade the collagen of the extracellular matrix; the matrix is made up of secreted molecules that help glue endothelial cells together. One of these degradation products is N-α-PGP.
N-α-PGP has long been known to act as a signal that attracts neutrophils — the white blood cells that are the first line of defense to engulf infecting bacteria or respond to injury — thanks to seminal work conducted by Roswell Pfister, M.D., and J. Edwin Blalock, Ph.D., at UAB. The N-α-PGP acts on the neutrophil’s CXC chemokine receptor 2 (CXCR2). Since endothelial cells also have those receptors, the senior co-authors — Rakesh Patel, Ph.D., UAB Department of Pathology, and Amit Gaggar, M.D., Ph.D., UAB Department of Medicine — decided to test whether N-α-PGP might also act as a signal upon endothelial cells. Now, they and colleagues report the first evidence that N-α-PGP acts on the endothelial cell CXCR2 receptors and activates the downstream signaling that is seen for other pathogenic factors that disrupt vascular permeability.
|This discovery could lead to therapy to target ARDS, and also other human diseases that have extracellular matrix turnover and blood vessel leakage, including reperfusion of organs after they have been cut off from oxygen, lung vascular disease, kidney injury and heart attacks. In all of these, the critical biological function of the endothelium is altered by inflammation or disease.|
This showed a role for N-α-PGP as a novel effector of endotoxin-induced injury.
“LPS is a very generic sledgehammer,” Gaggar said. “The fact that you could attenuate that was eye-opening.”
This first example of RTR’s targeting endothelial permeability in vivo suggests that endogenous bioactive PGP-containing peptides help mediate lung fluid accumulation in ARDS.
“That tells us that this is important in vivo,” Patel said.
The other vivid experiment was in cell cultures with ARDS patient samples. The research team showed that blood plasma from ARDS patients increased the permeability of endothelial cells in vitro; but if RTR was added to the plasma, it blocked about 15-20 percent of that increased permeability — presumably by acting on N-α-PGP.
“As a clinician,” said Gaggar, a pulmonologist who cares for patients in the ICU setting, “I find it very exciting to think there is something that is targetable that might become a therapy for ARDS.”
The title of the paper is “The matrikine N-α-PGP couples extracellular matrix fragmentation to endothelial permeability.”
The first three authors of the paper contributed equally. The first two are Cornelia S. Hahn, M.D., Ph.D., and David W. Scott, Ph.D., who did the research as a UAB Department of Medicine internal medicine resident and a UAB Department of Pathology graduate student, respectively, and are now both at the University of North Carolina-Chapel Hill. The third author is Xin Xu, M.D., Ph.D., UAB Department of Medicine. The other authors are Mojtaba Abdul Roda, Pharm.D., Gregory A. Payne, M.D., J. Michael Wells, M.D., Liliana Viera, Ph.D., Preston Bratcher, Ph.D., Patricia L. Jackson, Ph.D., and J. Edwin Blalock, Ph.D., UAB Department of Medicine; Colleen J. Winstead, Ph.D., UAB Department of Pathology; and Rolf W. Sparidans, Ph.D., Frank A. Redegeld, Ph.D., and Gert Folkerts, Ph.D., Utrecht University, the Netherlands.